Medicare Part B drug payments to 340B hospitals “declined substantially” in 2019 because the payment status of “an unusually high number of drugs” changed that year, congressional Medicare advisers said in a report yesterday.
The change—from “pass-through status” to “separately
…
President Biden has nominated Melanie Egorin, a veteran Democratic congressional health care adviser, to serve as U.S. Health and Human Services (HHS) Assistant Secretary for Legislation.
If confirmed, Egorin would be a top deputy to Xavier Becerra, whose nomination to
…
The Biden administration proposes once again to push back, this time from March 22 to July 20, the effective date of the Trump administration’s controversial final rule to require health centers to provide insulin and injectable epinephrine to low-income patients
…
Drug manufacturer Sanofi on Monday struck back at the U.S. Justice Department (DOJ) for opposing its Feb. 2 motion in a federal lawsuit requesting an injunction against the 340B program’s new administrative dispute resolution (ADR) process.
“The government is eager
…
The U.S. House on Wednesday passed and sent to President Biden a $1.9 trillion COVID-19 relief and economic recovery bill with provisions affecting the 340B program and its participants. Biden will sign the bill at the White House tomorrow.
The
…
The U.S. Senate voted 50 to 49 along party lines early Saturday morning to approve an amended version of the House’s $1.9 trillion COVID-19 relief bill. According to House Majority Leader Steny Hoyer’s (D-Md.) office, the House could vote on
…
Hospital groups that recently filed a motion to intervene in opposition to drug manufacturer Eli Lilly’s lawsuit against the federal government over 340B contract pharmacy requirements also are trying to intervene in similar suits against the government by manufacturers AstraZeneca,
…
The U.S. Senate Finance Committee yesterday split 14-14 along party lines on whether to favorably report California Attorney General Xavier Becerra’s nomination to serve as U.S. Health and Human Services (HHS) secretary to the full Senate.
There is a 50-50
…
More than 70 percent of U.S. spending on top-selling “partial orphan drugs”—drugs for rare diseases that also are approved to treat common diseases—is for non-orphan indications, a study in latest edition of Health Affairs concludes.
Makers of partial orphan drugs
…*Sign up for news summaries and alerts from 340B Report